OptiNose Says US FDA Extended Review of Supplemental New Drug Application for Xhance in Chronic Rhinosinusitis
OptiNose Says US FDA Extended Review of Supplemental New Drug Application for Xhance in Chronic Rhinosinusitis
OptiNose表示，美國食品藥品管理局延長了對慢性鼻竇炎Xhance補充新藥申請的審查
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊